SHINVA(SH:600587)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥2,112,972,293.22, representing a decrease of 16.05% compared to the same period last year[6]. - The net profit attributable to shareholders of the listed company was ¥127,600,837.33, down 12.84% year-on-year[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 21.46%, amounting to ¥148,416,797.53, due to optimized product structure and increased market development efforts[6]. - Basic earnings per share were ¥0.31, down 13.89% year-on-year[6]. - Total revenue for Q1 2022 was ¥2,112,972,293.22, a decrease of 16.0% from ¥2,517,075,310.88 in Q1 2021[26]. - Net profit for Q1 2022 was ¥129,776,153.67, compared to ¥149,950,629.56 in Q1 2021, reflecting a decrease of 13.4%[30]. - The total comprehensive income for the first quarter of 2022 was CNY 130,548,364.12, compared to CNY 150,160,394.94 in the first quarter of 2021, representing a decrease of approximately 13.1%[32]. - The basic and diluted earnings per share for the first quarter of 2022 were both CNY 0.31, down from CNY 0.36 in the first quarter of 2021, reflecting a decrease of approximately 13.9%[32]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥353,160,624.57, a decline of 207.19% compared to the previous year[6]. - The net cash flow from operating activities for the first quarter of 2022 was negative CNY 353,160,624.57, a significant decline from a positive CNY 329,475,154.58 in the same period last year[34]. - Cash inflow from operating activities totaled CNY 2,540,053,632.68, down from CNY 3,205,161,549.51 in the first quarter of 2021, indicating a decrease of about 20.7%[34]. - The total cash and cash equivalents at the end of the first quarter of 2022 were CNY 1,147,806,980.50, compared to CNY 1,031,930,548.33 at the end of the first quarter of 2021, showing an increase of about 11.2%[34]. - The company's cash and cash equivalents decreased to 1,411,820,184.27 RMB from 1,567,234,539.30 RMB at the end of 2021[21]. - The total amount of receivables increased to 1,605,707,625.67 RMB from 1,574,008,292.94 RMB at the end of 2021[21]. - The company reported a decrease in cash inflow from the sale of goods and services, which was CNY 2,361,813,687.27 in the first quarter of 2022, down from CNY 3,088,771,939.26 in the first quarter of 2021, a decline of about 23.5%[34]. Assets and Liabilities - Total assets at the end of the reporting period were ¥12,254,998,665.62, an increase of 5.52% from the end of the previous year[9]. - Total assets as of the end of the reporting period were ¥12,254,998,665.62, an increase from ¥11,613,893,656.00 at the end of the previous period[26]. - Total liabilities increased to ¥6,856,008,077.32 from ¥6,345,464,086.08, representing a rise of 8.0%[26]. - The equity attributable to shareholders increased to ¥5,043,468,357.59 from ¥4,914,714,269.04, reflecting a growth of 2.6%[26]. - The company maintained a stable level of deferred tax assets at ¥56,385,797.47, compared to ¥69,664,744.97 in the previous period[26]. Operational Challenges and Adjustments - The decline in operating revenue was primarily due to decreased sales in the medical trade segment[11]. - The company's revenue and net profit have decreased compared to the same period last year due to the termination of the agency business with Johnson & Johnson by its subsidiary, Shanghai Taimei Medical Equipment Co., Ltd.[18]. - The company has initiated cooperation with a new partner after the termination of the previous agency, which is expected to gradually restore performance[18]. - The company is actively adjusting its operational arrangements to mitigate the impact of COVID-19 lockdowns on production and shipping[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 28,432[12]. - The company reported a total of 116,947,642 shares held by Shandong Yiyang Health Industry Development Group Co., Ltd., the largest shareholder[15]. Investment and Expenses - Research and development expenses increased to ¥54,260,023.18 in Q1 2022, up 13.5% from ¥47,746,955.65 in Q1 2021[30]. - The cash outflow for employee compensation increased to CNY 436,512,972.39 in the first quarter of 2022, compared to CNY 343,685,062.00 in the same period last year, marking an increase of approximately 27%[34]. - The net cash flow from investing activities was negative CNY 64,632,017.25, worsening from negative CNY 13,654,056.21 year-over-year[34]. - The net cash flow from financing activities improved to CNY 243,800,320.80 in the first quarter of 2022, compared to a negative cash flow of CNY 446,453,570.54 in the same quarter of 2021[34].